About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cd19tm1(cre)Cgn
targeted mutation 1, University of Cologne
MGI:1931143
Summary 155 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn involves: 129P2/OlaHsd MGI:2175750
cn2
Cd19tm1(cre)Cgn/Cd19+
Ifnar1tm1Uka/Ifnar1tm1Uka
B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka MGI:3829380
cn3
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn MGI:3690548
cn4
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn Tg(Cd4-cre)1Cwi MGI:3690549
cn5
Cd19tm1(cre)Cgn/Cd19+
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
B6.Cg-Cd1d1tm1.1Aben Cd19tm1(cre)Cgn MGI:5318544
cn6
Cd19tm1(cre)Cgn/Cd19+
Gna11tm1Soff/Gna11tm1Soff
Gnaqtm2Soff/Gnaqtm2Soff
B6N.129-Cd19tm1(cre)Cgn Gna11tm1Soff Gnaqtm2Soff MGI:3699321
cn7
Cd19tm1(cre)Cgn/Cd19+
Klhl6tm2Sato/Klhl6tm2Sato
either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1) MGI:3605618
cn8
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6) MGI:5004802
cn9
Tnftm1.1Sned/Tnftm1.1Sned
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 MGI:3527259
cn10
Prelid1tm1Hmva/Prelid1tm1Hmva
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6 MGI:5437512
cn11
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1.1Mgin
involves: 129 * C57BL/6 * SJL MGI:3843276
cn12
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1Yai
involves: 129 * C57BL/6 * SJL MGI:3843277
cn13
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
involves: 129P2/OlaHsd MGI:4453321
cn14
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
Tg(Lck-cre)I57Jxm/0
involves: 129P2/OlaHsd MGI:4453323
cn15
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd MGI:4460905
cn16
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd MGI:3055676
cn17
Cd19tm1(cre)Cgn/Cd19+
Cxcr4tm2Yzo/Cxcr4tm2Yzo
involves: 129P2/OlaHsd MGI:3526527
cn18
Cd19tm1(cre)Cgn/Cd19+
Igbp1tm1Imku/Y
involves: 129P2/OlaHsd MGI:3603798
cn19
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:5574113
cn20
Pgap3tm1Ymra/Pgap3tm1Ymra
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:5538667
cn21
Brca2tm1Brn/Brca2tm1Brn
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:5495980
cn22
Casp8tm1Hed/Casp8tm1Hed
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:3697395
cn23
Brca2tm1Brn/Brca2tm1Brn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:5495979
cn24
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
involves: 129P2/OlaHsd MGI:5291647
cn25
Srftm2Nor/Srftm2Nor
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:3843267
cn26
Cd19tm1(cre)Cgn/Cd19+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd MGI:4355202
cn27
Cd19tm1(cre)Cgn/Cd19+
Derl2tm1.1Hpl/Derl2tm1.1Hpl
involves: 129P2/OlaHsd MGI:4947223
cn28
Cxcr4tm2Yzo/Cxcr4tm3.1Yzo
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd MGI:4878990
cn29
Ezh2tm1Tara/Ezh2tm1Tara
Cd19tm1(cre)Cgn/?
involves: 129P2/OlaHsd MGI:4440626
cn30
Cd19tm1(cre)Cgn/Cd19+
Rapgef2tm1.1Hous/Rapgef2tm1.1Hous
involves: 129P2/OlaHsd * 129S1/Sv MGI:4839186
cn31
Pik3cdtm1Tnr/Pik3cdtm1Tnr
Ptentm2.1Ppp/Ptentm2.1Ppp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6 MGI:3796508
cn32
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 MGI:4437066
cn33
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 MGI:5305096
cn34
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 MGI:4437062
cn35
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 MGI:5305095
cn36
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6 MGI:5305097
cn37
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:3608659
cn38
Cd19tm1(cre)Cgn/Cd19+
Prdm1tm1Clme/Prdm1tm1Clme
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:3606173
cn39
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6 MGI:5476680
cn40
Nle1tm1Cba/Nle1tm1.1Cota
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas MGI:5553374
cn41
Cd19tm1(cre)Cgn/Cd19+
Pax5tm1Mbu/Pax5tm3Mbu
involves: 129P2/OlaHsd * 129S2/SvPas MGI:3720352
cn42
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ MGI:5314090
cn43
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ MGI:5314093
cn44
Cd19tm1(cre)Cgn/Cd19+
Ell2tm1.1Cmil/Ell2tm1.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 MGI:5793061
cn45
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 MGI:5314096
cn46
Cd19tm1(cre)Cgn/Cd19+
Tnfsf13btm1Msc/Tnfsf13btm1Msc
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 MGI:3777352
cn47
Cd19tm1(cre)Cgn/Cd19+
Ell2tm2.1Cmil/Ell2tm2.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 MGI:5793062
cn48
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 MGI:5314091
cn49
Itgavtm2Hyn/Itgavtm2.1Hyn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB MGI:3759846
cn50
Cd19tm1(cre)Cgn/Cd19+
Kmt2atm1.1Erns/Kmt2atm1.1Erns
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL MGI:3839883
cn51
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae MGI:4829792
cn52
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae MGI:5013951
cn53
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae MGI:4829791
cn54
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5007685
cn55
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:2684441
cn56
Rbbp8tm1Whl/Rbbp8tm1.1Thl
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor MGI:5484529
cn57
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 MGI:5495974
cn58
Zc3h12ctm2c(EUCOMM)Hmgu/Zc3h12ctm2c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N MGI:6359749
cn59
Cd19tm1(cre)Cgn/Cd19+
Pbx1tm2Mlc/Pbx1tm2Mlc
involves: 129P2/OlaHsd * 129S6/SvEvTac MGI:3783742
cn60
Brca1tm2Cxd/Brca1tm2Cxd
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac MGI:5495978
cn61
Brca1tm2Cxd/Brca1tm2Cxd
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac MGI:5495977
cn62
Blmtm4Ches/Blmtm4Ches
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac MGI:5484530
cn63
Myctm2Fwa/Myctm2Fwa
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac MGI:2385667
cn64
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J MGI:5301628
cn65
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J MGI:5301629
cn66
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J MGI:5295466
cn67
Ptpmt1tm2.1Ckq/Ptpmt1tm2.1Ckq
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL MGI:5485996
cn68
Traf3tm1Bshp/Traf3tm1Bshp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL MGI:3722773
cn69
Blmtm4Ches/Blmtm4Ches
Cd19tm1(cre)Cgn/Cd19+
Nsmce2tm2.1Ofc/Nsmce2tm2.1Ofc
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL MGI:5906762
cn70
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
Rac2tm1Mddw/Rac2tm1Mddw
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 MGI:2684442
cn71
Cd19tm1(cre)Cgn/Cd19+
Tnftm2.1Gkl/Tnftm2.1Gkl
involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J MGI:3629600
cn72
Cd19tm1(cre)Cgn/Cd19+
Mcl1tm2Sjk/Mcl1tm3Sjk
involves: 129P2/OlaHsd * 129X1/SvJ MGI:2684157
cn73
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac MGI:5442608
cn74
Cd19tm1(cre)Cgn/Cd19+
Gna12tm1Citb/Gna12tm1Citb
Gna13tm2.1Soff/Gna13tm2.1Soff
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N MGI:3699320
cn75
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1Uzs/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c MGI:3811554
cn76
Cd19tm1(cre)Cgn/Cd19+
Tgfbr2tm1Roes/Tgfbr2tm1Roes
involves: 129P2/OlaHsd * BALB/c MGI:3051965
cn77
Cd19tm1(cre)Cgn/Cd19+
Srsf3tm1Pjln/Srsf3tm1Pjln
involves: 129P2/OlaHsd * BALB/c MGI:3687457
cn78
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(CTNNB1)Nerl/Gt(ROSA)26Sortm1(CTNNB1)Nerl
involves: 129P2/OlaHsd * BALB/c MGI:3706810
cn79
Cd19tm1(cre)Cgn/Cd19+
Fastm1Ach/Fastm1Ach
involves: 129P2/OlaHsd * BALB/c MGI:3720605
cn80
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 MGI:5567931
cn81
Cd19tm1(cre)Cgn/Cd19+
Il10ratm1.1Jack/Il10ratm1.1Jack
involves: 129P2/OlaHsd * BALB/c * C57BL/6 MGI:4437331
cn82
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ MGI:5314103
cn83
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 MGI:5314085
cn84
Cd19tm1(cre)Cgn/Cd19+
Ikbkgtm1.1Mpa/Y
involves: 129P2/OlaHsd * C57BL/6 MGI:3851695
cn85
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Cgn/Ikbkbtm2.1Cgn
involves: 129P2/OlaHsd * C57BL/6 MGI:3851694
cn86
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
involves: 129P2/OlaHsd * C57BL/6 MGI:2654061
cn87
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm2Ama/Tnfaip3+
involves: 129P2/OlaHsd * C57BL/6 MGI:4831003
cn88
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:4850098
cn89
Cd19tm1(cre)Cgn/Cd19+
Irf8tm1.1Hm/Irf8tm1.1Hm
involves: 129P2/OlaHsd * C57BL/6 MGI:4939594
cn90
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 MGI:3809750
cn91
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
involves: 129P2/OlaHsd * C57BL/6 MGI:3809749
cn92
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
involves: 129P2/OlaHsd * C57BL/6 MGI:3809748
cn93
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5314087
cn94
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5314104
cn95
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 MGI:3777342
cn96
Sh2d1atm2Vei/Sh2d1atm2Vei
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:3775442
cn97
Cd19tm1(cre)Cgn/?
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
involves: 129P2/OlaHsd * C57BL/6 MGI:3772814
cn98
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
Tg(Lck-cre)1Jtak/?
involves: 129P2/OlaHsd * C57BL/6 MGI:3768341
cn99
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
involves: 129P2/OlaHsd * C57BL/6 MGI:3768340
cn100
Cd19tm1(cre)Cgn/Cd19+
Ptpn6tm1Rsky/Ptpn6tm1Rsky
involves: 129P2/OlaHsd * C57BL/6 MGI:3720197
cn101
Cd19tm1(cre)Cgn/Cd19+
Pdia3tm1Gjh/Pdia3tm1Gjh
involves: 129P2/OlaHsd * C57BL/6 MGI:3702091
cn102
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5502352
cn103
Tab2tm2.1Aki/Tab2tm2.1Aki
Tab3tm1Aki/Tab3tm1Aki
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5502699
cn104
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5517353
cn105
Cd19tm1(cre)Cgn/Cd19+
Spi1tm2Dgt/Spi1tm2Dgt
involves: 129P2/OlaHsd * C57BL/6 MGI:3688724
cn106
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 MGI:3687542
cn107
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5780067
cn108
Kmt2dtm1.1Kaig/Kmt2d+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5780069
cn109
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 MGI:3687509
cn110
Cd19tm1(cre)Cgn/Cd19+
Map3k7tm1Aki/Map3k7tm1.1Aki
involves: 129P2/OlaHsd * C57BL/6 MGI:3664610
cn111
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5825356
cn112
Pax5tm3Mbu/Pax5+
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:5825360
cn113
Cd19tm1(cre)Cgn/Cd19+
Ube2ntm1Aki/Ube2ntm1Aki
involves: 129P2/OlaHsd * C57BL/6 MGI:3656029
cn114
Cd19tm1(cre)Cgn/Cd19+
Cxcr4tm1Tng/Cxcr4tm2Tng
involves: 129P2/OlaHsd * C57BL/6 MGI:3639683
cn115
Tnfaip3tm2Ama/Tnfaip3tm2Ama
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 MGI:4831002
cn116
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm1Cgn/Ikbkbtm1.1Cgn
involves: 129P2/OlaHsd * C57BL/6 MGI:3851693
cn117
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74*)Awai/Gt(ROSA)26Sor+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd * C57BL/6 MGI:3814893
cn118
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74*)Awai/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 MGI:3814891
cn119
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 MGI:3809751
cn120
Adam10tm1.1Dhc/Adam10tm1.1Dhc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL MGI:4438893
cn121
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
Tg(Vav-BCL2)1Jad/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL MGI:3804187
cn122
Rnaseh2btm1c(EUCOMM)Wtsi/Rnaseh2btm1c(EUCOMM)Wtsi
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL MGI:5911410
cn123
Mcm3aptm1Imku/Mcm3aptm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:3584126
cn124
Cd19tm1(cre)Cgn/Cd19+
Notch2tm2Hhi/Notch2tm1.1Hhi
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:2663723
cn125
Pcid2tm1Imku/Pcid2tm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:4843145
cn126
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:3710554
cn127
Cd19tm1(cre)Cgn/Cd19+
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:3710553
cn128
Cd19tm1(cre)Cgn/Cd19+
Notch2tm1.1Hhi/Notch2+
involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:4360762
cn129
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL MGI:3690553
cn130
Nabp2tm1.1Nfel/Nabp2tm1.2Nfel
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL MGI:5448645
cn131
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
involves: 129P2/OlaHsd * C57BL/6 * MRL MGI:3690552
cn132
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1Rbr/Birc3tm1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB MGI:5013716
cn133
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB MGI:5013717
cn134
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 * NZB MGI:5013718
cn135
Rc3h1tm1.1Mass/Rc3h1tm1.1Mass
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL MGI:5301604
cn136
Cd19tm1(cre)Cgn/Cd19+
Ctnnbl1tm1.1Crad/Ctnnbl1tm1.1Crad
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:5795711
cn137
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:3777347
cn138
Cd19tm1(cre)Cgn/Cd19+
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:3777344
cn139
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:3804190
cn140
Ebf1tm1.1Rug/Ebf1tm1.1Rug
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:5316373
cn141
H2-Ab1tm1Wug/H2-Ab1tm1Wug
Cd19tm1(cre)Cgn/Cd19+
involves: 129S2/SvPas * C57BL/6 MGI:5543897
cn142
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 MGI:3843174
cn143
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Mka/Ikbkbtm2Mka
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 MGI:2657004
cn144
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * FVB/N MGI:3843175
cn145
Tbk1tm1Arte/Tbk1tm1Arte
Map3k14tm1Rds/Map3k14tm1Rds
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6 MGI:5446431
cn146
Tbk1tm1Arte/Tbk1tm1Arte
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6 MGI:5446428
cx147
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
Malt1tm1Mak/Malt1tm1Mak
involves: 129P2/OlaHsd MGI:5908455
cx148
Bcl10tm1Mak/Bcl10tm1Mak
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd MGI:5908454
cx149
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd MGI:5908453
cx150
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
involves: 129P2/OlaHsd * C57BL/6 MGI:5007683
cx151
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * C57BL/6 MGI:5007684
cx152
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm1Mnz/Ightm1Mnz
involves: 129P2/OlaHsd * C57BL/6 MGI:3714748
cx153
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm2Mnz/Ightm2Mnz
involves: 129P2/OlaHsd * C57BL/6 MGI:3712644
cx154
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 MGI:5013719
cx155
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * C57BL/6 * NZB MGI:2665858


Genotype
MGI:2175750
hm1
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• reduced numbers of B1 cells (Cd23-, IgM hi, IgD lo) (J:27463)
• failure of germinal center formation (J:27463)
• impaired B cell response to T cell dependent antigens; mutants exhibit a decreased hapten-specific antibody response by an NP-chicken-gamma-globulin conjugate
• failure of affinity maturation of serum antibodies
• absence of high-affinity NP-specific IgG1 antibody following immunization with NP-chicken-gamma-globulin conjugate
• reduction in serum IgM

hematopoietic system
• reduced numbers of B1 cells (Cd23-, IgM hi, IgD lo) (J:27463)
• failure of germinal center formation (J:27463)
• impaired B cell response to T cell dependent antigens; mutants exhibit a decreased hapten-specific antibody response by an NP-chicken-gamma-globulin conjugate
• failure of affinity maturation of serum antibodies
• absence of high-affinity NP-specific IgG1 antibody following immunization with NP-chicken-gamma-globulin conjugate
• reduction in serum IgM




Genotype
MGI:3829380
cn2
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ifnar1tm1Uka/Ifnar1tm1Uka
Genetic
Background
B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ifnar1tm1Uka mutation (0 available); any Ifnar1 mutation (33 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• serum IgG1 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgG2a levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgG3 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgM levels are markedly decreased compared to controls 10- days after immunization with soluble antigen + IFNalpha stimulation

hematopoietic system
• serum IgG1 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgG2a levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgG3 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation
• serum IgM levels are markedly decreased compared to controls 10- days after immunization with soluble antigen + IFNalpha stimulation




Genotype
MGI:3690548
cn3
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
Genetic
Background
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Fastm1Cgn mutation (1 available); any Fas mutation (47 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fastm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Faslpr homozygotes




Genotype
MGI:3690549
cn4
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
Genetic
Background
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn Tg(Cd4-cre)1Cwi
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Fastm1Cgn mutation (1 available); any Fas mutation (47 available)
Tg(Cd4-cre)1Cwi mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fastm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Faslpr homozygotes




Genotype
MGI:5318544
cn5
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
Genetic
Background
B6.Cg-Cd1d1tm1.1Aben Cd19tm1(cre)Cgn
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Cd1d1tm1.1Aben mutation (1 available); any Cd1d1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• mice exhibit normal development, distribution and activation of NK T cells




Genotype
MGI:3699321
cn6
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Gna11tm1Soff/Gna11tm1Soff
Gnaqtm2Soff/Gnaqtm2Soff
Genetic
Background
B6N.129-Cd19tm1(cre)Cgn Gna11tm1Soff Gnaqtm2Soff
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gna11tm1Soff mutation (0 available); any Gna11 mutation (4 available)
Gnaqtm2Soff mutation (0 available); any Gnaq mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• double deficient B cells do not show abnormalities is lysophospholipid-induced adhesion




Genotype
MGI:3605618
cn7
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Klhl6tm2Sato/Klhl6tm2Sato
Genetic
Background
either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Klhl6tm2Sato mutation (0 available); any Klhl6 mutation (34 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• impaired development past the immature stage
• reduced number of B220+ and CD3- B lymphocytes in spleen and peripheral blood
• impaired germinal center formation

hematopoietic system
• impaired development past the immature stage
• reduced number of B220+ and CD3- B lymphocytes in spleen and peripheral blood




Genotype
MGI:5004802
cn8
Allelic
Composition
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm1(gp80,EGFP)Eces mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

A representative tumor in the nose of a Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+ mouse

mortality/aging
• mice succumb to tumors between 7 and 19 months of age

immune system
• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice
• mice exhibit fewer IgG1+ B cells compared to in wild-type mice
• in the spleen with a slight reduction in the splenic B to T cell ratio
• in non-immunized and immunized mice starting at 2 to 3 months of age
• in non-immunized and immunized mice
• NP-stimulated
• NP-stimulated
• resting and NP-stimulated
• resting and NP-stimulated
• resting and NP-stimulated

neoplasm
• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region
• histocytic/dendritic cell sarcoma

hematopoietic system
• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice
• mice exhibit fewer IgG1+ B cells compared to in wild-type mice
• in the spleen with a slight reduction in the splenic B to T cell ratio
• in non-immunized and immunized mice starting at 2 to 3 months of age
• in non-immunized and immunized mice
• NP-stimulated
• NP-stimulated
• resting and NP-stimulated
• resting and NP-stimulated
• resting and NP-stimulated

cellular




Genotype
MGI:3527259
cn9
Allelic
Composition
Tnftm1.1Sned/Tnftm1.1Sned
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129 * 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Tnftm1.1Sned mutation (0 available); any Tnf mutation (35 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• susceptibility to LPS, S. aureus, and Listeria monocytoegenes infection and liver injury was not different from wild-type and no differences in serum TNF levels were detected, indicating that B cell derived Tnf does not play a role in toxicity, host defense, or autoimmunity




Genotype
MGI:5437512
cn10
Allelic
Composition
Prelid1tm1Hmva/Prelid1tm1Hmva
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129 * 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Prelid1tm1Hmva mutation (0 available); any Prelid1 mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• viable and fertile with no discernible B cell abnormalities




Genotype
MGI:3843276
cn11
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1.1Mgin
Genetic
Background
involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Slc3a2tm1.1Mgin mutation (0 available); any Slc3a2 mutation (13 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• minimal proliferation in response to anti-IgM antibody stimulation
• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells

immune system
N
• despite Cre mediated deletion in B cells, mice have normal pre-B, pro-B, immature and mature B cell numbers and normal splenic architecture
• defect in the ability of LPS stimulated isolated B cells to differentiate into plasma cells
• however, in a small percentage of cells where Cre mediated recombination did not take place plasma cell differentiation is normal
• decrease in germinal center B cell and plasma cell numbers 1 week after immunization
• however, by 2 - 3 weeks after immunization antigen specifc antibody titers are similar to controls suggesting strong selection in germinal centers for the few cells that escaped Cre mediated recombination and expression analysis confirms the presence of B cells expressing SLC3A2 in the germinal centers
• impaired antibody secretion following LPS stimulation
• impaired class switching following LPS stimulation
• activated B cells fail to spread after antibody mediated ligation of integrins
• minimal proliferation in response to anti-IgM antibody stimulation
• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells
• decrease in basal and antigen specific levels of IgG
• decrease in antigen specific levels of IgM
• however, basal IgM levels are similar to controls

hematopoietic system
• defect in the ability of LPS stimulated isolated B cells to differentiate into plasma cells
• however, in a small percentage of cells where Cre mediated recombination did not take place plasma cell differentiation is normal
• decrease in germinal center B cell and plasma cell numbers 1 week after immunization
• however, by 2 - 3 weeks after immunization antigen specifc antibody titers are similar to controls suggesting strong selection in germinal centers for the few cells that escaped Cre mediated recombination and expression analysis confirms the presence of B cells expressing SLC3A2 in the germinal centers
• impaired antibody secretion following LPS stimulation
• impaired class switching following LPS stimulation
• activated B cells fail to spread after antibody mediated ligation of integrins
• minimal proliferation in response to anti-IgM antibody stimulation
• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells
• decrease in basal and antigen specific levels of IgG
• decrease in antigen specific levels of IgM
• however, basal IgM levels are similar to controls




Genotype
MGI:3843277
cn12
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1Yai
Genetic
Background
involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Slc3a2tm1.1Mgin mutation (0 available); any Slc3a2 mutation (13 available)
Slc3a2tm1Yai mutation (0 available); any Slc3a2 mutation (13 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• decrease in antigen specific levels of IgG3
• decrease in antigen specific levels of IgM

hematopoietic system
• decrease in antigen specific levels of IgG3
• decrease in antigen specific levels of IgM




Genotype
MGI:4453321
cn13
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ltbrtm1Avt mutation (0 available); any Ltbr mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• susceptibility to Citrobacter rodentium infection is similar to wild-type controls




Genotype
MGI:4453323
cn14
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
Tg(Lck-cre)I57Jxm/0
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ltbrtm1Avt mutation (0 available); any Ltbr mutation (3 available)
Tg(Lck-cre)I57Jxm mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• susceptibility to Citrobacter rodentium infection is similar to wild-type controls




Genotype
MGI:4460905
cn15
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm1(ITK/SYK)Jrld mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Enlarged spleen and solid organ infiltration with abnormally proliferating T cells in Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+ mice

endocrine/exocrine glands
• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice
• lymphomas consists of enlarged, activated, and highly proliferative T cells

cellular
• lymphomas consists of enlarged, activated, and highly proliferative T cells

mortality/aging
• mice develop lethal wasting and die by 60 weeks of age unlike wild-type mice

immune system
• at 50 weeks
• lymphomas consists of enlarged, activated, and highly proliferative T cells
• lymphomas consists of enlarged, activated, and highly proliferative T cells

neoplasm
• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice
• lymphomas consists of enlarged, activated, and highly proliferative T cells

growth/size/body
• mice develop lethal wasting unlike wild-type mice

hematopoietic system
• at 50 weeks
• lymphomas consists of enlarged, activated, and highly proliferative T cells
• lymphomas consists of enlarged, activated, and highly proliferative T cells




Genotype
MGI:3055676
cn16
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm1(DTA)Riet mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• B cell but not T cell numbers are reduced in the bone marrow and spleen to 65% and 50% of control, respectively
• B cell turn over is also increased in double mutants

immune system
• B cell but not T cell numbers are reduced in the bone marrow and spleen to 65% and 50% of control, respectively
• B cell turn over is also increased in double mutants




Genotype
MGI:3526527
cn17
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Cxcr4tm2Yzo mutation (1 available); any Cxcr4 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• B cell precursors are found in the blood
• a large number of the B cell precursors die before they can complete the differentiation process
• the total number of mature B cells in the spleen is reduced to about 65% of wild-type
• the peritoneal B1 cell population is reduced in young and old mutants
• the peritoneal B2 cell population is reduced only in older mutants
• a greater than 20-fold reduction in the number of T cell independent antigen-specific plasma cells in the bone marrow is seen after immunization with Ficoll
• the number of antibody-secreting cells is reduced in the bone marrow and increased in the spleen 9 days after immunization, however long-term antibody production is not impaired
• basal levels of serum IG of all isotypes are reduced

immune system
• B cell precursors are found in the blood
• a large number of the B cell precursors die before they can complete the differentiation process
• the total number of mature B cells in the spleen is reduced to about 65% of wild-type
• the peritoneal B1 cell population is reduced in young and old mutants
• the peritoneal B2 cell population is reduced only in older mutants
• a greater than 20-fold reduction in the number of T cell independent antigen-specific plasma cells in the bone marrow is seen after immunization with Ficoll
• the number of antibody-secreting cells is reduced in the bone marrow and increased in the spleen 9 days after immunization, however long-term antibody production is not impaired
• basal levels of serum IG of all isotypes are reduced
• B cell follicles are more dispersed, frequently occur deep in the lamina propria, and some have enlarged T cell zones




Genotype
MGI:3603798
cn18
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Igbp1tm1Imku/Y
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Igbp1tm1Imku mutation (0 available); any Igbp1 mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• impaired proliferative responses, failure of G1/S transition

immune system
• no somatic hypermutation takes place
• decreased B220+ cells but cells have a normal maturation phenotype
• decreased numbers involve IgM+ IgDhi
• CD23+IgM+ follicular cells in the spleen were reduced as were CD40+ cells
• reduced in numbers although normal numbers of pro B cells are present in bone marrow
• germinal center formation is impaired
• impaired proliferative responses, failure of G1/S transition
• stimulated antibody production is low
• T cell dependent antibody production more affected than T cell independent production

hematopoietic system
• no somatic hypermutation takes place
• decreased B220+ cells but cells have a normal maturation phenotype
• decreased numbers involve IgM+ IgDhi
• CD23+IgM+ follicular cells in the spleen were reduced as were CD40+ cells
• reduced in numbers although normal numbers of pro B cells are present in bone marrow
• germinal center formation is impaired
• impaired proliferative responses, failure of G1/S transition
• stimulated antibody production is low
• T cell dependent antibody production more affected than T cell independent production




Genotype
MGI:5574113
cn19
Allelic
Composition
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• of follicular II B cells in the spleen
• of follicular I and follicular II B cells in the spleen
• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro
• impaired marginal zone B cell differentiation
• reduced number of class switched IgG1 B cells in the Peyer's patch
• almost complete block of class switch to IgA, IgG1, IgG2b and IgG3
• absence of the marginal zone B cells peripheral to follicles in the spleen
• increased percentage in the peritoneal cavity
• decreased follicular II B cell compartment and increase in follicular I B cell numbers in the spleen
• following immunization with NP-CG antigen
• however, levels in naive mice are normal
• following immunization with NP-CG antigen
• in naive mice and following immunization with NP-Ficoll
• in naive mice and following immunization with NP-Ficoll
• however, levels are normal following immunization with NP-CG antigen
• reduced development with reduced number of class switched IgG1 B cells in the Peyer's patch

cellular
• of follicular II B cells in the spleen
• of follicular I and follicular II B cells in the spleen
• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro

hematopoietic system
• of follicular II B cells in the spleen
• of follicular I and follicular II B cells in the spleen
• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro
• impaired marginal zone B cell differentiation
• reduced number of class switched IgG1 B cells in the Peyer's patch
• almost complete block of class switch to IgA, IgG1, IgG2b and IgG3
• absence of the marginal zone B cells peripheral to follicles in the spleen
• increased percentage in the peritoneal cavity
• decreased follicular II B cell compartment and increase in follicular I B cell numbers in the spleen
• following immunization with NP-CG antigen
• however, levels in naive mice are normal
• following immunization with NP-CG antigen
• in naive mice and following immunization with NP-Ficoll
• in naive mice and following immunization with NP-Ficoll
• however, levels are normal following immunization with NP-CG antigen




Genotype
MGI:5538667
cn20
Allelic
Composition
Pgap3tm1Ymra/Pgap3tm1Ymra
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Pgap3tm1Ymra mutation (1 available); any Pgap3 mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• mice do not develop anti-DNA antibodies




Genotype
MGI:5495980
cn21
Allelic
Composition
Brca2tm1Brn/Brca2tm1Brn
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca2tm1Brn mutation (3 available); any Brca2 mutation (33 available)
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Trp53bp1tm1Jc mutation (1 available); any Trp53bp1 mutation (69 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with cells from Brca2tm1Brn/Brca2tm1Brn Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn mice




Genotype
MGI:3697395
cn22
Allelic
Composition
Casp8tm1Hed/Casp8tm1Hed
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Casp8tm1Hed mutation (1 available); any Casp8 mutation (32 available)
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• modest reduction in B1 cells (~10%) in peritoneal cavity is seen
• reduction in percentage of marginal zone B cells is observed
• spleen cell number is increased ~30% compared to wild-type
• in response to LPS and dsRNA, B cells have decreased proliferative response
• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells
• mice mount an inferior IgM response to LPS immunization

hematopoietic system
• in response to LPS and dsRNA, B cells have decreased proliferative response
• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells
• modest reduction in B1 cells (~10%) in peritoneal cavity is seen
• reduction in percentage of marginal zone B cells is observed
• spleen cell number is increased ~30% compared to wild-type
• mice mount an inferior IgM response to LPS immunization

cellular
• cells treated with LPS or dsRNA show decreased survival (increased apoptosis) compared to controls at 24 hours, with decreased viability starting at 12 hours
• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells
• in response to LPS and dsRNA, B cells have decreased proliferative response
• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells




Genotype
MGI:5495979
cn23
Allelic
Composition
Brca2tm1Brn/Brca2tm1Brn
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca2tm1Brn mutation (3 available); any Brca2 mutation (33 available)
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with untreated cells




Genotype
MGI:5291647
cn24
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Tnfaip3tm1.1Awai mutation (0 available); any Tnfaip3 mutation (28 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular

immune system
• in the bone marrow
• in the spleen and lymph nodes
• in mesenteric lymph nodes and Peyer's patches
• in the spleen and lymph nodes
• in unstimulated and NP-CG-stimulated mice
• in unstimulated and NP-CG-stimulated mice

hematopoietic system
• in the bone marrow
• in the spleen and lymph nodes
• in mesenteric lymph nodes and Peyer's patches
• in the spleen and lymph nodes
• in unstimulated and NP-CG-stimulated mice
• in unstimulated and NP-CG-stimulated mice




Genotype
MGI:3843267
cn25
Allelic
Composition
Srftm2Nor/Srftm2Nor
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Srftm2Nor mutation (0 available); any Srf mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• overall reduction of CD19+ B cells in bone marrow
• reduced surface expression of IgM in cells from the spleen, lymph nodes, bone marrow and blood
• surface expression of IgD is not affected
• in spite of normal follicular architecture
• CD19+ IgM+ CD5+ peritoneal B cells are decreased in number

hematopoietic system
• overall reduction of CD19+ B cells in bone marrow
• in spite of normal follicular architecture
• CD19+ IgM+ CD5+ peritoneal B cells are decreased in number
• reduced surface expression of IgM in cells from the spleen, lymph nodes, bone marrow and blood
• surface expression of IgD is not affected




Genotype
MGI:4355202
cn26
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Il10tm1Roer/Il10tm1Roer
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Il10tm1Roer mutation (0 available); any Il10 mutation (31 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• increased B cell numbers are observed after immunization with anti-IgD antibody compared to immunized controls
• plasma cell numbers are 2-fold larger than controls seven days after infection with MCMV
• are observed after immunization with anti-IgD antibody compared to immunized controls
• increased myeloid numbers are observed after immunization with anti-IgD antibody compared to immunized controls
• MCMV-specific CD8 + T cell numbers are about twice as numerous as controls 7 days after infection with MCMV
• IL-10 levels are half that of wild-type controls when immunized with anti-IgD antibodies

homeostasis/metabolism
• IL-10 levels are half that of wild-type controls when immunized with anti-IgD antibodies

hematopoietic system
• increased B cell numbers are observed after immunization with anti-IgD antibody compared to immunized controls
• plasma cell numbers are 2-fold larger than controls seven days after infection with MCMV
• are observed after immunization with anti-IgD antibody compared to immunized controls
• increased myeloid numbers are observed after immunization with anti-IgD antibody compared to immunized controls
• MCMV-specific CD8 + T cell numbers are about twice as numerous as controls 7 days after infection with MCMV




Genotype
MGI:4947223
cn27
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Derl2tm1.1Hpl/Derl2tm1.1Hpl
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Derl2tm1.1Hpl mutation (0 available); any Derl2 mutation (14 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• B cell development and antibody secretion are normal




Genotype
MGI:4878990
cn28
Allelic
Composition
Cxcr4tm2Yzo/Cxcr4tm3.1Yzo
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Cxcr4tm2Yzo mutation (1 available); any Cxcr4 mutation (10 available)
Cxcr4tm3.1Yzo mutation (0 available); any Cxcr4 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• B cell precursors are released into the peripheral blood and reduced in the spleen unlike in wild-type mice but not as severely as in Cxcr4tm1Yzo homozygotes

immune system
• B cell precursors are released into the peripheral blood and reduced in the spleen unlike in wild-type mice but not as severely as in Cxcr4tm1Yzo homozygotes




Genotype
MGI:4440626
cn29
Allelic
Composition
Ezh2tm1Tara/Ezh2tm1Tara
Cd19tm1(cre)Cgn/?
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ezh2tm1Tara mutation (2 available); any Ezh2 mutation (53 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• mice exhibit normal B cell development and normal in vitro proliferation of splenic B cells in response to anti-IgM F(ab)2, anti-CD40 or LPS




Genotype
MGI:4839186
cn30
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Rapgef2tm1.1Hous/Rapgef2tm1.1Hous
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Rapgef2tm1.1Hous mutation (1 available); any Rapgef2 mutation (48 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• mice exhibit normal adult hematopoiesis

immune system
N
• mice exhibit normal B cell and T cell development




Genotype
MGI:3796508
cn31
Allelic
Composition
Pik3cdtm1Tnr/Pik3cdtm1Tnr
Ptentm2.1Ppp/Ptentm2.1Ppp
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Pik3cdtm1Tnr mutation (0 available); any Pik3cd mutation (14 available)
Ptentm2.1Ppp mutation (0 available); any Pten mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• unlike in Pten deficient mice, B1 B cell numbers are normal in the spleen and peritoneum
• defects in class switch recombination associated with Pten deficiency are partially reversed
• mice exhibit an increase in marginal zone B cells that is not as great as in Pten null mice but more than in wild-type mice

hematopoietic system
• defects in class switch recombination associated with Pten deficiency are partially reversed
• mice exhibit an increase in marginal zone B cells that is not as great as in Pten null mice but more than in wild-type mice




Genotype
MGI:4437066
cn32
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Mirc30tm1.1Rdf mutation (1 available); any Mirc30 mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• fraction of mice have histological features of small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL)
• some of the CD5 negative tumors showed a mature B cell phenotype histologically reminiscent of human diffuse large B cell lymphoma, non-Hodgkin lymphoma
• a minority of CD5 negative tumors showed plasmacytic features similar to lymphoplasmacytic lymphoma

hematopoietic system
• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age
• at 15-18 months increased clonal population in the peripheral blood
• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

immune system
• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age
• at 15-18 months increased clonal population in the peripheral blood
• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice




Genotype
MGI:5305096
cn33
Allelic
Composition
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Del(14Trim13-Rnaseh2b)6Rdf mutation (0 available); any Del(14Trim13-Rnaseh2b)6Rdf mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 70% of mice die by 20 months

neoplasm
• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

immune system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 25% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo

hematopoietic system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 25% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo




Genotype
MGI:4437062
cn34
Allelic
Composition
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Del(14Trim13-Dleu2)4Rdf mutation (0 available); any Del(14Trim13-Dleu2)4Rdf mutation (0 available)
Is(14)1Rdf mutation (0 available); any Is(14)1Rdf mutation (0 available)
Is(14)2Rdf mutation (1 available); any Is(14)2Rdf mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age
• at 15-18 months increased clonal population in the peripheral blood
• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

immune system
• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age
• at 15-18 months increased clonal population in the peripheral blood
• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

neoplasm
• a fraction of mice have histological features of small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL)
• some of the CD5 negative tumors showed a mature B cell phenotype histologically reminiscent of human diffuse large B cell lymphoma, non-Hodgkin lymphoma
• a minority of CD5 negative tumors showed plasmacytic features similar to lymphoplasmacytic lymphoma




Genotype
MGI:5305095
cn35
Allelic
Composition
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Del(14Trim13-Rnaseh2b)6Rdf mutation (0 available); any Del(14Trim13-Rnaseh2b)6Rdf mutation (0 available)
Is(14)1Rdf mutation (0 available); any Is(14)1Rdf mutation (0 available)
Is(14)5Rdf mutation (1 available); any Is(14)5Rdf mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

neoplasm
• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

immune system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 42% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo

hematopoietic system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 42% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo




Genotype
MGI:5305097
cn36
Allelic
Composition
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Is(14)1Rdf mutation (0 available); any Is(14)1Rdf mutation (0 available)
Is(14)5Rdf mutation (1 available); any Is(14)5Rdf mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

neoplasm
• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

immune system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 67% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo

hematopoietic system
• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220lo) with characteristics of chronic lymphocytic leukemia
• 67% of mice develop clonal lymphoproliferations
• IgM+CD5+B220lo




Genotype
MGI:3608659
cn37
Allelic
Composition
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bak1tm1Thsn mutation (2 available); any Bak1 mutation (16 available)
Baxtm1Sjk mutation (1 available); any Bax mutation (24 available)
Baxtm2Sjk mutation (1 available); any Bax mutation (24 available)
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• 4-fold increase in the number of CD43+IgM- Pro-B cells
• relative number of CD21highCD23low marginal zone B cells is decreased
• increase in the number of B cells at all stages of development in the bone marrow and spleen
• a 3-5 fold increase in the numbers of transitional B cells
• an increase in B-2 cell number, but not B-1 cells, from the peritoneal cavity
• an increase in CD21intCD23high follicular B cells
• a 4-fold increase in the number of IgM+ immature B cells
• B cells are highly resistant to multiple cell death stimuli, including cytokine withdrawal, BCR crosslinking, steroid treatment, and DNA damage
• cell cycle progression of splenic B cells is impaired after stimulation with mitogens LPS and anti-IgM, but not CpG-DNA
• all isotypes were 5-10 times higher than controls
• increased IgG1, IgG2, IgG2b and IgG3

hematopoietic system
• 4-fold increase in the number of CD43+IgM- Pro-B cells
• 2-fold increase in total cellularity of bone marrow cells, due to accumulation of developing B cells
• relative number of CD21highCD23low marginal zone B cells is decreased
• increase in the number of B cells at all stages of development in the bone marrow and spleen
• a 3-5 fold increase in the numbers of transitional B cells
• an increase in B-2 cell number, but not B-1 cells, from the peritoneal cavity
• an increase in CD21intCD23high follicular B cells
• a 4-fold increase in the number of IgM+ immature B cells
• B cells are highly resistant to multiple cell death stimuli, including cytokine withdrawal, BCR crosslinking, steroid treatment, and DNA damage
• cell cycle progression of splenic B cells is impaired after stimulation with mitogens LPS and anti-IgM, but not CpG-DNA
• all isotypes were 5-10 times higher than controls
• increased IgG1, IgG2, IgG2b and IgG3




Genotype
MGI:3606173
cn38
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Prdm1tm1Clme/Prdm1tm1Clme
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Prdm1tm1Clme mutation (1 available); any Prdm1 mutation (19 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• following immunization a severe decrease in the number of antigen-specific IgM secreting cells is seen compared to wild-type mice
• a larger increase in CD138-B220+NP+ B cells expressing GL7 is seen at 7 and 14 days after immunization
• the development of both short-lived and post-germinal center long-lived plasma cells is blocked in mutants
• pre-plasma memory B-cells are reduced by 75% in the spleen and 95% in the bone marrow, and CD138-B220+NP+ cells comprise the majority of memory B cells
• antibody stimulating cell development is completely inhibited in cultures of stimulated B cells, however stimulation of B cells with LPS or LPS and IL-4 results in increased class switch recombination (J:114881)
• very few CD138+B220+/- plasma cells are seen at any time before or after immunization
• 5 days after re-challenge a 99% reduction in CD138+ B220+/- NP+ plasma cells is seen
• more numerous germinal centers are seen after immunization
• larger germinal centers are seen after immunization
• serum Ig levels are reduced in unimmunized mice
• in mice immunized with NP-Ficoll serum IgG1 and IgG2a levels are significantly lower in mutants compared to wild-type mice and mutant mice fail to secrete Ig in a recall response
• in mice immunized with NP-Ficoll serum IgM levels are significantly lower in mutants compared to wild-type mice and homozygous mice fail to secrete Ig in a recall response

hematopoietic system
• following immunization a severe decrease in the number of antigen-specific IgM secreting cells is seen compared to wild-type mice
• a larger increase in CD138-B220+NP+ B cells expressing GL7 is seen at 7 and 14 days after immunization
• the development of both short-lived and post-germinal center long-lived plasma cells is blocked in mutants
• pre-plasma memory B-cells are reduced by 75% in the spleen and 95% in the bone marrow, and CD138-B220+NP+ cells comprise the majority of memory B cells
• antibody stimulating cell development is completely inhibited in cultures of stimulated B cells, however stimulation of B cells with LPS or LPS and IL-4 results in increased class switch recombination (J:114881)
• very few CD138+B220+/- plasma cells are seen at any time before or after immunization
• 5 days after re-challenge a 99% reduction in CD138+ B220+/- NP+ plasma cells is seen
• more numerous germinal centers are seen after immunization
• larger germinal centers are seen after immunization
• serum Ig levels are reduced in unimmunized mice
• in mice immunized with NP-Ficoll serum IgG1 and IgG2a levels are significantly lower in mutants compared to wild-type mice and mutant mice fail to secrete Ig in a recall response
• in mice immunized with NP-Ficoll serum IgM levels are significantly lower in mutants compared to wild-type mice and homozygous mice fail to secrete Ig in a recall response




Genotype
MGI:5476680
cn39
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Trp53tm1Yjc mutation (0 available); any Trp53 mutation (152 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• mice do not develop B cell lymphomas




Genotype
MGI:5553374
cn40
Allelic
Composition
Nle1tm1Cba/Nle1tm1.1Cota
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Nle1tm1.1Cota mutation (0 available); any Nle1 mutation (0 available)
Nle1tm1Cba mutation (0 available); any Nle1 mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells
• mice exhibit normal survival, proliferation and maturation of restricted progenitors

immune system
N
• mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells
• mice exhibit normal survival, proliferation and maturation of restricted progenitors




Genotype
MGI:3720352
cn41
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Pax5tm1Mbu/Pax5tm3Mbu
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Pax5tm1Mbu mutation (1 available); any Pax5 mutation (19 available)
Pax5tm3Mbu mutation (1 available); any Pax5 mutation (19 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• LPS-stimulated lymph node B cells exhibit a low frequency of and a delay in increased cell size relative to wild-type cells
• IgG class switching is decreased
• short-lived IgM-B220lo and IgM+B220lo immature B cells are slightly lower in number
• there is a 3-fold reduction in the number of long-lived mature B cells
• mice lack recirculating IgM+IgD+B220hi cells in the bone marrow
• short-lived IgM-B220lo B cells are slightly lower in number
• total immunoglobin is reduced 3-fold compared to control mice
• IgG levels are decreased ranging from a 9.4-fold decrease of IgG1 to a 2-fold decrease in IgG3 levels

hematopoietic system
• LPS-stimulated lymph node B cells exhibit a low frequency of and a delay in increased cell size relative to wild-type cells
• IgG class switching is decreased
• short-lived IgM-B220lo and IgM+B220lo immature B cells are slightly lower in number
• there is a 3-fold reduction in the number of long-lived mature B cells
• mice lack recirculating IgM+IgD+B220hi cells in the bone marrow
• short-lived IgM-B220lo B cells are slightly lower in number
• total immunoglobin is reduced 3-fold compared to control mice
• IgG levels are decreased ranging from a 9.4-fold decrease of IgG1 to a 2-fold decrease in IgG3 levels




Genotype
MGI:5314090
cn42
Allelic
Composition
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (510 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (87 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

immune system

hematopoietic system




Genotype
MGI:5314093
cn43
Allelic
Composition
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (510 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (87 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

immune system

liver/biliary system
• occasionally

neoplasm
• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

hematopoietic system




Genotype
MGI:5793061
cn44
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ell2tm1.1Cmil/Ell2tm1.1Cmil
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ell2tm1.1Cmil mutation (0 available); any Ell2 mutation (27 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T3 cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) percentage of immature B cells in bone marrow is increased as compared to control
• following antigen challenge (NP-Ficoll or NP-KLH)
• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells
• 4 fold decrease in LPS-treated B220loCD138+ splenic B cells
• decline in CD138+ cells in immunized mice
• following antigen challenge (NP-Ficoll or NP-KLH) percentage of recirculating B cells in bone marrow is increased as compared to control
• following antigen challenge (NP-Ficoll or NP-KLH)
• 2 fold decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotopes is found in naive mice as compared to controls
• specific antibody responses are impaired for both T cell dependent and independent antigens
• mice immunized with NP-Ficoll exhibit less anti-NP antibody of the IgM, IgG2b and IgG3 isotypes
• mice immunized with NP-KLH exhibit less anti-NP antibody of the IgM, IgG1, IgG2c and IgG3 isotopes
• following restimulation, recall response is less than controls

hematopoietic system
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) fewer T3 cells are observed in spleen
• following antigen challenge (NP-Ficoll or NP-KLH) percentage of immature B cells in bone marrow is increased as compared to control
• following antigen challenge (NP-Ficoll or NP-KLH)
• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells
• 4 fold decrease in LPS-treated B220loCD138+ splenic B cells
• decline in CD138+ cells in immunized mice
• following antigen challenge (NP-Ficoll or NP-KLH) percentage of recirculating B cells in bone marrow is increased as compared to control
• following antigen challenge (NP-Ficoll or NP-KLH)
• 2 fold decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotopes is found in naive mice as compared to controls

cellular
• ER found in LPS-treated B220loCD138+ cells is dilated and fragmented




Genotype
MGI:5314096
cn45
Allelic
Composition
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (87 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

immune system

liver/biliary system
• occasionally

neoplasm
• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

hematopoietic system




Genotype
MGI:3777352
cn46
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Tnfsf13btm1Msc/Tnfsf13btm1Msc
Traf2tm1Rbr/Traf2tm1Rbr
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Tnfsf13btm1Msc mutation (1 available); any Tnfsf13b mutation (19 available)
Traf2tm1Rbr mutation (0 available); any Traf2 mutation (9 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• there is about a 4-fold increase in the number of follicular B cells found in the spleen compared to controls
• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

hematopoietic system
• there is about a 4-fold increase in the number of follicular B cells found in the spleen compared to controls
• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes




Genotype
MGI:5793062
cn47
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ell2tm2.1Cmil/Ell2tm2.1Cmil
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ell2tm2.1Cmil mutation (0 available); any Ell2 mutation (27 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells
• decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotypes is found in naive mice as compared to controls

immune system
• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells
• decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotypes is found in naive mice as compared to controls




Genotype
MGI:5314091
cn48
Allelic
Composition
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation (0 available); any Gt(ROSA)26Sor mutation (510 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (87 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

immune system

hematopoietic system




Genotype
MGI:3759846
cn49
Allelic
Composition
Itgavtm2Hyn/Itgavtm2.1Hyn
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Itgavtm2.1Hyn mutation (0 available); any Itgav mutation (8 available)
Itgavtm2Hyn mutation (2 available); any Itgav mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• mice do not develop colitis unlike Itgavtm2Hyn Itgavtm2.1Hyn Tg(Tek-cre)1Ywa mice




Genotype
MGI:3839883
cn50
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Kmt2atm1.1Erns/Kmt2atm1.1Erns
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Kmt2atm1.1Erns mutation (0 available); any Kmt2a mutation (79 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• mice exhibit normally differentiating T, B, and myeloid cells




Genotype
MGI:4829792
cn51
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ptentm1Hwu/Ptentm1Hwu
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• the population of B1 and MZ B cells that are absent in single homozygous CD19 mutants is restored
• mutants are capable of forming germinal centers when immunized with sheep red blood cells




Genotype
MGI:5013951
cn52
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Inpp5dtm1Rav mutation (1 available); any Inpp5d mutation (39 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not
• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

behavior/neurological
• mutants exhibit a hunched posture by 4 months of age
• mutants exhibit lethargy by 4 months of age

growth/size/body
• mutants exhibit weight loss by 4 months of age

hematopoietic system
• CD19+ B cells are larger than B cells from wild-type mice
• B cell neoplasia
• reduction in the frequency of B cells in asymptomatic double mutant mice as compared to controls or either single mutant mouse
• mutants older than 6 months of age have a 3-fold increase in the percentage of recirculating B cells in the blood, concurrent with onset of disease
• tissues containing the expanded B cell population also display an expansion of CD11b+ myeloid cells
• mutants exhibit splenomegaly by 4 months of age
• spleens of mutants over 6 months of age exhibit an expansion of CD19+ B cells, resulting in enlarged white pulp areas that often infiltrate and compress the red pulp
• B cells exhibit enhanced survival
• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not
• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

immune system
• CD19+ B cells are larger than B cells from wild-type mice
• B cell neoplasia
• reduction in the frequency of B cells in asymptomatic double mutant mice as compared to controls or either single mutant mouse
• mutants older than 6 months of age have a 3-fold increase in the percentage of recirculating B cells in the blood, concurrent with onset of disease
• tissues containing the expanded B cell population also display an expansion of CD11b+ myeloid cells
• mutants exhibit splenomegaly by 4 months of age
• spleens of mutants over 6 months of age exhibit an expansion of CD19+ B cells, resulting in enlarged white pulp areas that often infiltrate and compress the red pulp
• B cells exhibit enhanced survival
• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not
• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

integument
• mutants exhibit ruffled fur by 4 months of age

mortality/aging
• severe morbidity and death occurs in all mutants by 1 year of age

neoplasm
• mutants develop marginal zone lymphoma, and less frequently, follicular B cell lymphoma or centroblastic lymphoma
• mutants develop spontaneous and lethal mature B cell neoplasms consistent with marginal zone lymphoma
• lymphoma infiltrates are seen in nonlymphoid tissues, including liver, lung, heart, and kidney

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
B-cell lymphoma DOID:707 J:166155




Genotype
MGI:4829791
cn53
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• bone marrow cultured with IL-7 over a 6 day period to promote selective expansion of pre-B cells exhibits an approximate 7-fold enhancement in the frequency of activated immature mutant B cells relative to immature wild-type B cells
• gating on activated B cells shows that immature mutant B cells proliferate to a much greater extent than immature wild-type B cells
• these experiments show that upon BCR engagement, immature B cells are activated and proliferate rather than being inhibited and undergoing anergy
• increase in the absolute number of splenic B cells, attributed mainly to the expansion/accumulation of MZ B cells
• expansion of the B1 cell population
• expansion of the MZ B cell compartment
• increase in numbers of IgMhi antibody secreting cells and decrease in numbers of IgGhi antibody secreting cells
• reduction in germinal center formation in response to sheep red blood cell immunization and in response to environmental antigens
• B cells are responsive to chemotactic stimuli but show reduced directed movement toward the stimulus
• cultured B cells show increased apoptosis
• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)
• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)
• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)
• impaired class-switch recombination in antibody secreting cells in response to a T-dependent antigen; B cells fail to undergo class-switch recombination to IgG3 or IgG1 in the presence of LPS or LPS plus IL-4, respectively
• however, well-formed germinal centers are observed in spleen after immunization
• decrease in IgG after TNP-OVA immunization
• increase in IgM after TNP-OVA immunization

immune system
• bone marrow cultured with IL-7 over a 6 day period to promote selective expansion of pre-B cells exhibits an approximate 7-fold enhancement in the frequency of activated immature mutant B cells relative to immature wild-type B cells
• gating on activated B cells shows that immature mutant B cells proliferate to a much greater extent than immature wild-type B cells
• these experiments show that upon BCR engagement, immature B cells are activated and proliferate rather than being inhibited and undergoing anergy
• increase in the absolute number of splenic B cells, attributed mainly to the expansion/accumulation of MZ B cells
• expansion of the B1 cell population
• expansion of the MZ B cell compartment
• increase in numbers of IgMhi antibody secreting cells and decrease in numbers of IgGhi antibody secreting cells
• reduction in germinal center formation in response to sheep red blood cell immunization and in response to environmental antigens
• B cells are responsive to chemotactic stimuli but show reduced directed movement toward the stimulus
• cultured B cells show increased apoptosis
• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)
• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)
• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)
• impaired class-switch recombination in antibody secreting cells in response to a T-dependent antigen; B cells fail to undergo class-switch recombination to IgG3 or IgG1 in the presence of LPS or LPS plus IL-4, respectively
• however, well-formed germinal centers are observed in spleen after immunization
• decrease in IgG after TNP-OVA immunization
• increase in IgM after TNP-OVA immunization

cellular
• cultured B cells show increased apoptosis
• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)
• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)
• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)




Genotype
MGI:5007685
cn54
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (38 available)
Tg(IghelMD4)4Ccg mutation (3 available)
Tg(ML5sHEL)5Ccg mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• failed tolerance induction resulting in abundant autoantibody production, indicating that B cells are prevented from acquiring an anergic state
• B cells have about 10 fold lower bound HEL than in mutants with intact Pten, suggesting that receptor occupancy is reduced on mutant autoreactive B cells and that less HEL is available in adults for inducing and sustaining anergy
• increasing the concentration of free self-antigen confers an anergic phenotype on mutant B cells, but they remain long-lived




Genotype
MGI:2684441
cn55
Allelic
Composition
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Rac1tm1Tyb mutation (0 available); any Rac1 mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• B lineage cells were normal in bone marrow, spleen, and lymph nodes




Genotype
MGI:5484529
cn56
Allelic
Composition
Rbbp8tm1Whl/Rbbp8tm1.1Thl
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJaeSor
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Rbbp8tm1.1Thl mutation (0 available); any Rbbp8 mutation (27 available)
Rbbp8tm1Whl mutation (0 available); any Rbbp8 mutation (27 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• B cells exhibit normal class switching and microhomology at Smu-Sgamma1 junctions




Genotype
MGI:5495974
cn57
Allelic
Composition
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (8 available); any Cd19 mutation (15 available)
Palb2tm1.1Dli mutation (1 available); any Palb2 mutation (30 available)
Trp53bp1tm1Jc mutation (1 available); any Trp53bp1 mutation (69 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• the number of chromosomal aberrations (ch